Wed 21 Oct 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| "Comparison of IV ketamine with Standard Analgesia for treatment of vaso occlusive crisis in sickle cell disease." | King Faisal Specialist Hospital & Research Centre Riyadh, Saudi Arabia | Ongoing | ESKETAMINE HCL | 3 | 2211021 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| A randomized double-blind placebo-controlled parallel group study assessing the efficacy and safety of dupilumab in patients with Allergic Fungal Rhinosinusitis (AFRS) | Sanofi | Ongoing | Dupilumab | 3 | EFC16724 | King Khalid University Hospital (Riyadh),King Faisal Specialist Hospital and Research Center (Riyadh) |
| A Phase 2 study of PHE885, B-cell maturation Antigen (BCMA)-directed CAR-T Cells in adult participants with relapsed and refractory multiple myeloma. | Novartis | Ongoing | PHE885 (CAR-T Cell) | 2 | CPHE885B12201 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| Stress Hydrocortisone in Pediatric Septic Shock (The SHIPSS trial) | King Abdullah International Medical Research Center (KAIMRC) | Ongoing | Hydrocortisone | 4 | SCT22R/009 | King Abdulaziz Medical City NG (Riyadh) |
| iOUTRUN: Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients | AstraZeneca | Ongoing | Benralizumab | 4 | D3250R0011 | King Fahad Medical City (Riyadh) , King Faisal Specialist Hospital and Research Center (Jeddah),International Medical Center (Jeddah) |
| "Nintedanib in patients with bronchiolitis obliterans syndrome following hematopoietic stem cell transplantation – a multicentre phase II trial" | King Faisal Specialist Hospital & Research Centre Riyadh, Saudi Arabia | Ongoing | NINTEDANIB | 2 | Amendment 3 F02 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| An open-label, controlled, multi-site, Phase 2 clinical trial to assess the ureagenesis capacity in newborns and infants up to the age of 12 months with neonatal and infantile onset of urea cycle disorders (UCD) using a 15N ammonium chloride tracer compared to newborns and infants without UCD | Unicyte AG,Aawasserstrasse 2, 6370 Oberdorf NW, Switzerland | Rejected | 15NH4Cl tracer assay | 2 | HLSC-UCD-01 | King Abdulaziz Medical City NG (Riyadh) |
| A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects with Propionic or Methylmalonic Acidemia Followed by a 6-Month, Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study and an Open-label, Long-term Extension Study | HemoShear Therapeutics, | Terminated | ST5040 (2,2-dimethylbutanoic acid) | 4 | HST20-CL01 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| An observational disease and clinical outcomes registry of patients with acid lipase (LAL) deficiency | Alexion Pharma | Ongoing | Kanuma | 4 | ALX-LALD-5 | King Faisal Specialist Hospital and Research Center (Riyadh) , King Abdulaziz Medical City NG (Riyadh) |
| A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature | Novo Nordisk | Ongoing | Sogroya , Norditropin | 3 | NN8640-4467 | King Faisal Specialist Hospital and Research Center (Riyadh) , King Abdulaziz Medical City NG (Riyadh) |
Last update date: 06/10/2026 at 08:14 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.